With the rapid pace of scientific breakthroughs in clinical development, an increasingly complex and diverse array of health technologies are emerging in Australia and overseas.

Over the past few decades, medicines are largely small molecules and biologicals, whereby their HTA pathways and associated funding programs are primarily considered at the Federal level. The emergence of cell and gene therapies, together with the rising use of genomics in screening and diagnostics, have raised questions on the extent to which HTA and funding harmonisation can (or should) be achieved for these individualised, high-cost technologies, while balancing the objective of achieving health equity. These questions are relevant when different jurisdictions and agencies have overlapping responsibilities in the assessment, funding and delivery of new health technologies.

This one-day workshop will bring together the perspectives from different stakeholders on the introduction of new health technologies in Australia, and how the trajectory of current HTA, funding and service delivery may need to evolve to accommodate the introduction of these highly specialised therapies.

Speakers include:

Andrew Partington | Flinders Health & Medical Research Institute
Prof Andrew Wilson | The University of Sydney (PBAC perspective)
Dr Paul Fennessy | Consultant (interstate perspective)
Julia Conway | IHACPA
Elizabeth de Somer | Medicines Australia
Sharon Winton | Lymphoma Australia
Adam Wardell | ANDHealth
Brendan Shaw | Consultant (international perspective)
Tiffany Boughtwood | Genomics Australia

The Event Program is now available! Check this link for further updates to the sessions.

Image credit: xpoint / iStockphoto.com